🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Teleflex Incorporated TFX R3KPHARMA

Healthcare · Medical Instruments & Supplies · United States
https://www.teleflex.com
Company Profile ↓
$137.00
+12.73% 1Y
Mkt Cap$5.81B
P/E-258.49
P/B1.82
Div. Yield1.08%
52W High$142.05
52W Low$99.54
Book Value$68.55
EPS (TTM)$-0.53

Company Overview

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and collection of blood samples; intraosseous access systems consisting of EZ-IO intraosseous vascular access systems, and Arrow FAST1 sternal intraosseous infusion systems; and hemostatic products, including external hemostats and trauma products under the QuikClot brand. It also provides interventional products, including various coronary catheters, structural heart support devices, and peripheral intervention products platforms; GuideLiner, Turnpike, and TrapLiner catheters; MANTA vascular closure devices and Arrow OnControl powered bone biopsy systems; and coronary and peripheral medical devices, such as drug-coated balloons, stents, and balloon catheters. In addition, the company offers surgical products, including metal and polymer ligating clips using manual and automatic applier system, fascial closure surgical systems used in laparoscopic surgical procedures, percutaneous surgical systems, powered bariatric staplers, and other surgical instruments under the Weck, MiniLap, Pleur-Evac, Deknatel, KMedic, Pilling, and Titan SGS brands. It serves hospitals, healthcare providers, and medical device manufacturers. The company also sells its products online. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

Why Investors Should Care

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $1.99B (+17.2% YoY); net profit $-905.64M.
  • Trailing 12 Months Year-on-year growth — revenue +28.9%, earnings -17.3%.
  • 5-Year Trend Long-term compounding — revenue CAGR 0.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:0.26%
1 Year:28.90%

Compounded Profit Growth

5 Years:-
1 Year:-17.30%

Stock Price Performance

1 Year:+12.73%
6 Months:+21.20%
3 Months:+4.25%
1 Month:+1.75%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 88% of range
$99.54 $142.05
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)49.45 · Neutral
Price Performance
1M+1.75%
3M+4.25%
6M+21.20%
1Y+12.73%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-258.49
Industry PE
24.83
Forward P/E
12.51
PEG Ratio
0.16
Book Value
$68.55
Price to Book
1.82
P/S
2.34
EV/EBITDA
19.53
Dividend Yield
1.08%

Growth (CAGR)

Revenue 5Y
0.26%
Profit 5Y
-
Revenue (YoY)
28.90%
Earnings (YoY)
-17.30%

Profitability & Returns

ROCE
4.14%
ROE
-0.70%
ROA
1.75%
Profit Margin
-45.76%
Op Margin
10.06%
Gross Margin
55.11%
EPS (Latest Qtr)
$2.28
EPS (TTM)
$-0.53

Balance Sheet & Liquidity

Debt/Equity
1.01
Quick Ratio
0.96
Current Ratio
2.60
Debt
$2.94B
Total Assets
$6.79B
Current Assets
$1.86B
Working Capital
$1.18B

Ownership

Promoter Holding
0.62%
Chg in Prom Hold
0.13%
FII / Inst Holding
114.56%
Chg in FII Hold
-0.11%

Financial Snapshot

Enterprise Value
$5.81B
Total Revenue (TTM)
$2.25B
EBITDA
$403.90M
Free Cash Flow
$179.54M
Operating Cash Flow
$403.20M
Shares Outstanding
42.37M
Gross Margin
55.11%
Payout Ratio
2,266.67%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 TFX Teleflex Incorporated R3KPHARMA 137.00 -258.49 $5.81B 1.08% 4.14% -0.70% 0.26% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Apr 2017Jul 2017Oct 2017Dec 2017Apr 2018Jul 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Apr 2023Jul 2023Oct 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue -----487.88M528.61M534.70M595.11M587.23M609.87M609.67M641.62M613.58M652.51M648.32M680.95M630.64M567.03M628.30M711.18M633.92M713.47M700.25M641.72M704.54M686.79M710.93M743.26M746.39M412.82M418.51M426.20M-414.26M780.89M913.02M-401.87M548.26M570.33M
Cost of Revenue ----------------------------------158.83M349.80M461.38M-250.45M240.84M-
Gross Profit 260.32M225.15M256.40M241.60M273.05M255.56M290.28M295.23M330.73M331.27M344.78M342.57M365.82M323.97M352.24M355.07M377.72M333.62M278.37M329.32M383.55M344.53M397.56M387.79M346.23M388.83M373.95M391.38M407.82M416.31M256.66M251.67M260.27M-255.43M431.08M451.64M-151.41M307.43M331.71M
Operating Expenses ----------------------------------178.21M253.60M338.99M13.24M270.40M-
Operating Income 96.75M67.50M98.44M86.49M67.03M60.82M110.20M110.35M90.90M86.84M33.49M82.11M119.27M75.24M107.46M117.62M126.93M157.09M38.81M132.09M95.08M103.43M128.62M240.97M103.54M135.16M132.44M114.97M143.56M165.31M-71.77M51.06M71.96M-77.22M177.48M112.65M-164.65M37.03M72.82M
EBITDA ----------------------------------115.91M251.38M-328.81M247.07M75.63M-
Interest Expense ----------------------------------18.54M21.71M31.84M28.13M25.72M-
Pretax Income ----------------------------------58.75M135.25M-438.58M218.94M-3.83M-
Tax Provision ----------------------------------6.42M12.66M-29.70M-30.78M1.01M-
Net Income 101.12M50.69M59.30M66.32M61.06M40.17M78.00M77.02M-42.66M56.18M-2.50M56.52M90.59M40.90M83.38M228.93M108.27M131.15M11.46M116.59M76.13M74.87M83.25M199.18M77.14M105.51M101.89M76.75M111.33M137.14M15.29M80.04M111.00M-95.00M122.58M-408.89M-714.33M-8.15M99.69M
Diluted EPS 2.091.041.261.401.300.861.671.65-0.911.20-0.051.211.930.871.774.852.292.780.242.461.611.581.764.201.632.232.161.622.352.900.321.692.36-2.072.77-9.24-16.15-0.182.28
R&D Expense -12.35M15.47M15.07M-17.83M20.28M21.19M-26.03M26.02M26.36M-27.15M27.59M27.98M-27.40M29.36M29.22M-29.95M33.28M31.82M36.36M36.93M37.77M41.47M39.45M37.58M37.30M41.09M38.73M-25.30M38.52M57.23M-44.39M45.12M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 1.91B1.43B1.40B1.49B1.55B1.70B1.84B1.81B1.87B2.15B2.45B2.60B2.54B-2.79B1.71B1.70B1.99B
Cost of Revenue --------------1.26B672.33M662.16M871.96M
Gross Profit 801.52M685.54M678.84M708.78M748.23M838.95M942.43M944.40M996.20M1.17B1.30B1.41B1.32B-1.53B1.04B1.04B1.12B
Operating Expenses --------------1.02B736.37M783.54M864.95M
Operating Income 238.96M250.23M230.29M229.57M-97.38M233.26M284.86M315.89M319.45M372.28M321.70M427.25M423.07M-513.52M303.75M253.85M255.80M
EBITDA --------------730.77M418.51M271.34M302.51M
Interest Expense --------------54.26M85.01M83.51M100.22M
Pretax Income --------------445.92M185.39M26.29M24.55M
Tax Provision --------------83.00M41.87M-30.90M-33.98M
Net Income 119.77M302.99M201.09M323.33M-190.06M150.88M187.68M244.86M237.38M152.53M200.80M461.47M335.32M-363.14M356.33M69.67M-905.64M
Diluted EPS 3.017.594.997.92-4.653.454.045.104.983.274.299.807.09-7.687.531.48-20.30
R&D Expense 32.60M36.69M42.38M48.71M56.28M65.05M61.04M52.12M58.58M84.77M106.21M113.86M119.75M130.84M153.82M113.63M109.02M144.78M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --3.84B3.64B3.92B3.73B4.21B3.92B3.87B3.89B6.18B6.28B6.31B7.15B-6.93B7.53B7.10B6.95B
Current Assets ---------------1.41B1.41B1.47B1.94B
Cash & Equivalents 201.34M107.28M188.31M208.45M584.09M337.04M431.98M303.24M338.37M543.79M333.56M357.16M301.08M375.88M-292.03M222.85M247.85M378.56M
Inventory ---------------578.51M626.22M306.77M404.39M
Receivables ---------------408.83M443.47M226.73M345.58M
Total Liabilities --2.25B1.86B1.94B1.95B2.29B2.01B1.86B1.75B3.75B3.74B3.33B3.82B-2.91B3.09B2.82B3.82B
Current Liabilities --337.11M420.76M271.01M275.30M635.12M632.77M664.12M427.65M483.88M582.46M563.05M540.03M-581.49M606.75M649.36M762.03M
Long Term Debt --1.19B813.41M954.81M965.28M930.00M700.00M641.85M850.25M2.16B2.07B1.86B2.38B-1.62B1.73B1.56B2.54B
Total Debt ---------------1.83B1.93B1.74B2.73B
Total Equity 1.37B1.29B1.58B1.78B1.98B1.78B1.91B1.91B2.01B2.14B2.43B2.54B2.98B3.34B-4.02B4.44B4.28B3.12B
Shares Outstanding ---------------47.96M48.05M48.10M48.20M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow --------------342.14M510.64M635.74M340.68M
Investing Cash Flow -----------196.39M-73.48M-837.78M--257.94M-621.23M-99.36M-849.19M
Financing Cash Flow ---1.13M--------206.43M-418.84M455.16M--217.51M38.54M-421.93M611.54M
Capital Expenditure -32.67M-26.34M-29.33M-44.58M-65.39M-63.58M-67.57M-61.45M-53.13M-70.90M-80.80M-102.69M-90.69M--79.19M-46.42M-90.44M-95.24M
Free Cash Flow --------------262.95M464.22M545.30M245.44M
Net Change in Cash ---------------133.31M-72.05M114.45M103.03M
Share Buybacks --------------00200.00M300.00M

Ratios (Annual)

Figures in %.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 41.9%47.8%48.6%47.5%48.2%49.5%51.2%52.2%53.3%54.6%53.2%54.3%52.2%-54.9%60.7%61.0%56.2%
Operating Margin % 12.5%17.4%16.5%15.4%-6.3%13.8%15.5%17.5%17.1%17.3%13.1%16.5%16.7%-18.4%17.7%14.9%12.8%
Net Margin % 6.3%21.1%14.4%21.7%-12.3%8.9%10.2%13.5%12.7%7.1%8.2%17.8%13.2%-13.0%20.8%4.1%-45.4%
ROE % 9.3%19.2%11.3%16.3%-10.7%7.9%9.8%12.2%11.1%6.3%7.9%15.5%10.1%-9.0%8.0%1.6%-29.0%
ROCE % -7.1%7.1%6.3%-2.8%6.5%8.7%9.8%9.2%6.5%5.6%7.4%6.4%-8.1%4.4%3.9%4.1%

Shareholding Pattern

Insiders
0.62%
Institutions
114.56%
Public Float
115.28%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 12.82% 5.43M $676.37M
2 Jupiter Topco LLC 10.25% 4.34M $540.73M
3 T. Rowe Price Investment Management, Inc. 7.54% 3.19M $397.81M
4 Vanguard Portfolio Management LLC 5.70% 2.42M $300.96M
5 Vanguard Capital Management LLC 4.71% 2.00M $248.51M
6 Sessa Capital IM, L.P. 3.60% 1.53M $190.05M
7 State Street Corporation 3.50% 1.48M $184.79M
8 Millennium Management Llc 3.40% 1.44M $179.57M
9 BAUPOST GROUP LLC/MA 3.33% 1.41M $175.45M
10 Fuller & Thaler Asset Management Inc. 3.12% 1.32M $164.48M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TFX

Google News Sat, 29 Aug 2026

Teleflex (TFX) Stock Trades At A Discount On Cash Flow But A Premium On Sales - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPOG45SS1JWXlmRS1Ya3Z0UG5LVkFJOWNqSFhqcnFLZklkNnhraXlULVR5SjFwRHJSVmFSckhyQkU1MExsS2YtQ1hFZ1dudGxoVkxhQzlkbjNWRDJWSlZjWUt3Mm1tWllPWG1NLVFjeWFnR1ZPNFhNZ0RfQ1U1eG15dXpZWDU3cDRZV0lwNW…

Google News Mon, 07 Sep 2026

Teleflex Incorporated (TFX): Stock Analysis Highlights A Promising 10.98% Upside Potential - directorstalkinterviews.com

<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxOYk44SjVMOEJmekhnS2xXYjVuRTcydkdaU0Z3Nm9JZF9zaVVyal8zR2FRaTlIRkZHQS1TLWZPX2JJVjlBMW5adGdrOU1hUlVaZHZzaWdXTGZNVDFoVDF6eDZoUUJnZ3JwcG1tVTl1N0RLak1xWUpfN2w1eUZOWVJfRktwd0UtYk5PMVp0d3…

Google News Fri, 04 Sep 2026

A leg stent study saw all procedures succeed through wrist access, Teleflex says. - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQTFR5VVNVUVdOaFpLQXlzZG00bExzQUpKZS1kYXJQNnpTYnFVRk1rT19OdHp2UE1FLW5vNkdCeVNkbUVxYlVjS2tzOXVyVU1JZHp5d3pKZjdxdmg5XzIyUHk5aEVxYnY1b3czaTA1TlF5bURReDBSbmZqNlV5MV9IVkdPRlZRbVdhZ0tSUV…

Google News Fri, 04 Sep 2026

Teleflex Stock Price Forecast. Should You Buy TFX? - StockInvest.us

<a href="https://news.google.com/rss/articles/CBMiR0FVX3lxTE5yaExKdFRZM1dQdTR2TExFcjVrRHp3NzRna2tvZVlnNE45SFpoaFd5N2ItRjZzblo1M0U0X1FzZzl5dmNIckk4?oc=5" target="_blank">Teleflex Stock Price Forecast. Should You Buy TFX?</a>&nbsp;&nbsp;<font…

Google News Sun, 06 Sep 2026

Is Teleflex (TFX) A Bargain On Its Dynetic 35 Showcase Plans? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPWVpKc0loSFFPX0JnTzNPb1lXQlZUc3UwbG16SmlTUi1OMThYY2lGV2tWN0d4b1h1WWRqMjkxWnZEYUFLTS0tbHJLWUZzeFBFSlFuZ01Pam0xT20yNUNzcDUzYzRhX254V0kxR0dCRE5NcGlCa3RjZjdQN1dYSExGUGo1bkdhMjM0emdlNm…

Google News hu, 07 May 2026

Why Is Teleflex (TFX) Stock Rocketing Higher Today - StockStory

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNbXFtamI3VWlRS0VEV19ycWo0UjltSWw0aWVaNkRBTlJXTy1TdjNqUlhsMGFNdFhIalMzU1p3MlgxUlRWcTlRZmhDc0ZHM2tDLWVkN21JMWhNU2tKbVloeE1zX0JzWnU1RmNQMjVtRUFPQkVIZTA0akQ4enBTWk5mdmVOMkU1QWVFeDhSZk…

TFX — Frequently Asked Questions

What is the current share price of Teleflex Incorporated (TFX)?

As of 2026-09-19 21:16 PDT, Teleflex Incorporated (TFX) trades at $137.00 on NYSE. Its 52-week range is $99.54 to $142.05.

What is the market capitalisation of TFX?

Teleflex Incorporated (TFX) has a market capitalisation of $5.81B on NYSE.

What is the P/E ratio of TFX?

TFX trades at a trailing price-to-earnings (P/E) ratio of -258.49. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.82.

Does TFX pay a dividend?

Teleflex Incorporated (TFX) currently offers a dividend yield of 1.08%.

What is the return on equity (ROE) of TFX?

TFX has a return on equity (ROE) of -0.70%. Its return on capital employed (ROCE) is 4.14%.

Is TFX a good stock to buy?

This page provides a data-driven analysis of Teleflex Incorporated (TFX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space